The present invention relates to amorphous sacubitril valsartan complex and its solid dispersion. The invention also relates to process for the preparation of sacubitril valsartan complex and its solid dispersion.

The present invention relates to process for preparation of ledipasvir of formula 1 and its novel intermediates. The process involves reaction of compound of formula 2 with compound of formula 3 to yield a compound of formula 4, deprotection of compound of formula 4 to yield compound of formula 5 and conversion of c...

The present invention relates to the process for preparation of crystalline form L of ilaprazole comprising steps of: i) heating the mixture of ilaprazole in aliphatic ketone containing tertiary organic amine, ii) cooling the mixture, iii) optionally seeding with form L andiv) isolating solid. The present invention ...

The present invention provides premix of ledipasvir comprising Ledipasvir and at least one pharmaceutically acceptable excipient, process for preparation of premix and pharmaceutical composition thereof and their use as medicaments.

The present invention relates to the novel compounds of the formula (I) and the process for their preparation. These novel compounds can be effectively used for the synthesis of Quinapril and its pharmaceutically acceptable salts.

The invention is related to high cell density fermentation process for production of heterologous proteins in E. coli expression system. The invention is also related to the process for the production of heterologous proteins in E. coli using pBAD24T7g10 vector. The invention is also related to the vector pBAD24T...

The present invention relates to the process for the preparation of glycerol phenylbutyrate (I) by reacting phenylbutyryl chloride (II) with glycerol (III) in presence of organic base in C1-C5 chlorinated solvent. Glycerol phenylbutyrate (I) prepared according the process of the present invention is having HPLC puri...

See Attachment

2Ferric citrate is provided having a BET active surface area in the range of 1 15 m /gm. A method for preparing pharmaceutical grade ferric citrate is also provided.

Compounds of the general formula (I) their tautomeric forms their stereoisomers their analogs their prodrugs their isotopes their N oxides their metabolites their pharmaceutically acceptable salts polymorphs solvates optical isomers clathrates co crystals combinations with suitable medicament pharmaceutical composit...

The invention relates to a cost effective, eco-friendly process for preparation of enantiomerically pure (S)-3-cyano-5-methyl-hexanoic acid alkyl ester, intermediate of y- amino acids, particularly (S)-pregabalin.

The present invention relates to a process for the preparation of amorphous form of dolutegravir comprising dissolving dolutegravir in a suitable solvent, removing the solvent and isolating the amorphous form of dolutegravir. The present invention further relates to the amorphous form of dolutegravir. ...

The present invention relates to a process for preparing the Ziprasidone hydrochloride monohydrate having mean particle size greater than 90 µm.

A process for preparation of optically pure or optically enriched enantiomers of sulphoxide compounds of formula (I), such as omeprazole and structurally related compounds, as well as their salts and hydrates. The said process comprises a) providing, a mixture of enantiomers of the sulphoxide compound of formula (I)...

The present invention relates to crystalline abacavir hydrochloride monohydrate. The present invention further provides a process for preparation of crystalline abacavir hydrochloride monohydrate by dissolving abacavir hydrochloride in aqueous C1-C4 alcoholic solvent, cooling the solution, and isolating the crystall...

A single layer pharmaceutical composition comprising active agent(s) amlodipine or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof wherein the composition exhibits bioequivalence to the commercially available bilayer tablet dosage form comprising amlodipine b...

The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the us...

A process for preparation of enantiomerically enriched and/or racemic γ-amino acids, particularly those useful for preparing γ-amino acids that exhibit binding affinity to the human Α2Δ calcium channel subunit, including pregabalin and related compounds such as 3-n-propyl-4-aminobutyric acid. ...

The present invention provides an improved process for Selexipag of formula (I) or its pharmaceutically acceptable salts.

A process for synthesis of 4S-phenyl -3-[(5S)-5-(4-fiuorophenyl)-5-hydroxypentanoyl] - 1,3 oxazolidin 2-one comprising resolution of 4S-phenyl -3-[(5RS)-5-(4-fluorophenyl)-5- hydroxypentanoyl] -1,3 oxazolidin 2-one by selective esterification of 4S-phenyl.-3- [(5R)-5-(4-fluorophenyl)-5-hydroxypentanoyl] -1,3 oxaz...

A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation compri...

The invention relates to a fusion tag comprising Serine-aspartic acid repeats of the well conserved region of the Staphylococcus aureus Sdr C gene superfamily. A START codon and an enterokinase cleavage site has been incorporated into this repeat region to make a novel fusion tag that is responsible for expressin...

14Disclosed are compounds of formula (I) their tautomeric forms stereoisomers and pharmaceutically acceptable salts thereof wherein R  R and n are as defined in the specification pharmaceutical compositions including a compound tautomer stereoisomer or salt thereof and methods of treating or preventing diseases or d...

N/A

A pharmaceutical composition comprising ramipril or pharmaceutically acceptable salts thereof and magnesium salts and lactic acid in a stabilizing effective amount to prevent cyclization and hydrolysis of ramipril or other related ACE inhibitors. A process for stabilizing ramipril pharmaceutically acceptable salts t...

The present invention relates to a novel process for the preparation of iloperidone (I) that comprises reaction of 1-[4-(3-halopropoxy)-3-methoxyphenyl] ethanone (IIIa / IIIb) with 6- fiuoro-3-(piperidine-4-yl)-1,2-benzisoxazole hydrochloride (II) under pressure in an autoclave.

N/A

The present invention provides process for preparation of dihydroxy benzoquinoline compound (III) comprising reacting dihydroxy isoquinoline compound (IV) or a salt thereof with (2-acetyl-4-methyl-pentyl)-trimethyl-ammonium iodide (V) and further converting it to tetrabenazine (I) and deutetrabenazine (II). ...

see attachment

The present invention provides a process forthe purification of norethindrone (I) from mixture of dimethyl formamide-water. The present invention further provides two processes for the purification of norethindrone acetate (II) from mixture of dichloromethane-n-heptane (Process A) and from mixture of methanol-water ...

N/A

The present invention relates to a process for preparation of optically pure enantiomer of Tolterodine Tartrate wherein the said process comprises of separation of racemic Tolterodine using suitable chiral BIQOL phosphoric acid compound as novel resolving agent.

The present invention relates to amorphous daclatasvir dihydrochloride and processes for its preparation.

Disclosed are compounds of formula (I) their tautomeric forms stereoisomers and pharmaceutically acceptable salts thereof wherein ring Ar ring B R1 R5 X Y p q r and s are as defined in the specification pharmaceutical compositions including a compound tautomer stereoisomer or salt thereof and methods of treating or ...

The invention provides refolding process of Ranibizumab wherein the solubilized solution of heavy chain and/or light chain of Ranibizumab treated with refolding buffer under suitable conditions including pH temperature and incubation period and the pH and temperature shift is performed at suitable interval to obtain...

Stable pharmaceutical formulations comprising human parathyroid hormone are provided. The stabilized aqueous pharmaceutical formulation comprises human parathyroid hormone and a buffer selected from lactate or glutamate. In another embodiment a stabilized aqueous pharmaceutical formulation comprising human parathyro...

The invention describes a process and diastereomeric salts useful for the optical resolution of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy] propyl] adenine and intermediates thereof. The process comprises placing into solution a chiral resolving agent, either L/D-Proline or ...

Disclosed are compounds of formula (I) their tautomeric forms stereoisomers and pharmaceutically acceptable salts thereof wherein R R R R A M n and p are as defined in the specification pharmaceutical compositions including a compound tautomer stereoisomer or salt thereof and methods of treating or preventing diseas...

Disclosed is a compound of formula (I): wherein D  ?  m  n and R R are as described herein as a modulator of nicotinic acetylcholine receptors particularly the a7 subtype in a subject in need thereof as well as analogues prodrugs isotopically substituted analogs metabolites pharmaceutically acceptable salts polymorp...

The invention provides the mammalian cell culture process for the production of monoclonal antibodies and fusion proteins wherein the mammalian cell is cultured in suitable cell culture conditions specifically maintaining monophasic temperature.

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes ...

Compounds of the general formula I their tautomeric forms their stereoisomers their analogs their prodrugs their isotopes their N oxides their metabolites their pharmaceutically acceptable salts polymorphs solvates optical isomers clathrates co crystals combinations with suitable medicament pharmaceutical compositio...

The present invention relates to novel substituted pyridone derivatives and processes for their preparation. The present invention further relates to the use of novel pyridone derivatives for the synthesis of carbamoylpyridone derivatives such as dolutegravir and cabotegravir.

Compounds of the general formula (I) their tautomeric forms their stereoisomers their analogs their prodrugs their isotopes their N oxides their metabolites their pharmaceutically acceptable salts polymorphs solvates optical isomers clathrates co crystals combinations with suitable medicament pharmaceutical composit...

The present invention relates to a premix of dapagliflozin with lactose, processes for its preparation, and pharmaceutical composition thereof. The invention also relates to a process for the preparation of an amorphous dapagliflozin and crystalline dapagliflozin propanediol hydrate.

The present invention provides a novel polymorphic form A of Warfarin Potassium and process of preparation of the form A. The form A is characterized by the XRPD pattern.

E. coliThe present invention relates to the dual independent cistron expression system in a single vector for the production of protein of interest proteins and peptides expressed as insoluble inclusion bodies formed in the bacteria .The present invention also provides the process for the expression of protein of in...

The present invention relates to a process for the preparation of duloxetine or pharmaceutically acceptable salt thereof involving novel intermediates of formula 6 and formula 7.

An inhaler device comprising: a housing (2), a base plate (4) covering the housing (2), a medicament holder (10) integrated with the base plate (4), a mouthpiece (3) sitting over the base plate (4), a lid (1) which covers the mouthpiece (3), at least one piercing element (11), an actuating member (5), a spring (12),...

The present invention relates to co-crystals of Metaxalone with Salicylamide, Nicotinamide and 4-hydroxy benzoic acid, and process for their preparation.

Disclosed herein an improved process for preparing (±)-cis sertraline and its pharmaceutically acceptable acid addition salt thereof comprising hydrogenation of 4-(3,4-dichlorophenyl)-3,4-dihydro-N-methyl-1- naphthalenimine by using chiral ligand (S)-BIQAP to obtain (±)-cis sertraline as pure product. ...

The present invention provides a novel amorphous form of lumacaftor and its preparation by various methods. The patent invention also relates to novel lumacaftor hydrobromide crystalline form A and process for its preparation. The present invention relates to amorphous lumacaftor premixed with an excipient and proce...

Disclosed herein a process for the isolation of intermediate of Vortioxetine in a solid state form and an improved, commercially viable and industrially advantageous process for the preparation of vortioxetine or a pharmaceutically acceptable salt thereof, in high yield and purity.

The invention relates to modified particles of crystalline Palbociclib free base is having a specific surface area in the range from 7 to 15 m2/g. The invention further relates to Palbociclib free base form B is having a specific surface area in the range from 3 to 15 m2/g and Palbociclib free base form A is having ...

The objective of the present invention is a one pot process for the preparation of pharmaceutical grade ferric citrate comprises of preparing a ferric hydroxide slurry followed by treatment with a citrate ion source to yield pharmaceutical grade ferric citrate.

Novel solvates of HIV protease inhibitor and processes for preparation thereof. These solvates of HIV protease inhibitor, particularly darunavir are stable, and viable at plant scale.

Novel method for synthesis of optically pure (S)-(-)-1,1'-bi-2-naphthol and/or (R)- (+)-1,1'-bi-2-naphthol via resolution of racemic (RS)-1,1'-bi-2-naphthol through formation of co-crystal with optically active derivatives of γ -amino acids.

The present invention relates to the crystalline form of dimethyl (3, 3-difluoro-2-oxoheptyl) phosphonate which is a useful intermediate for preparation of Lubiprostone.

The present invention provides cefixime trihydrate (I) with surface area of less than 1.2 m2/gm containing impurity A1 less than 0.5% by area percentage of HPLC.

The present invention provides novel salts of vortioxetine, viz., benzoate salt, succinate salt, salicylate salt, oxalate salt, citrate salt, L-malate salt of vortioxetine and process for their preparation.

The present invention provides crystalline Form M of Olaparib, amorphous form of Olaparib, process for their preparation, pharmaceutical composition thereof and their use as medicaments.

Present invention relates to a process for the preparation of (S)-4-(2-isopropyl-4-nitrobutyl)-1-methoxy-2-(3-methoxypropoxy) benzene [II], which is a key intermediate for synthesis of Aliskiren [I].

The present invention relates to a process for the preparation of duloxetine containing R-isomer less than 0.5 % by arylation of (S)-3-(methylamino)-1-(thiophen-2-yl)propan-1-ol with 1-fluoronaphathalene in presence of sodium amide and dimethyl sulfoxide.

The present invention is directed towards a manufacturing method for an iron containing adsorbent. Said iron containing adsorbent is characterized by a PSD d(0.9) in the range of 20 µm to 80 µm a BET active surface area less than 15 m2/g and a phosphate binding in the range of 35 to 60 mg/g.

The present invention is directed to process for preparation of a-form crystal of Mirabegron, (R)-2-(2-aminothiazol-4-yl)-N-(4-(2-((2-hydroxy-2-phenylethyl) amino) ethyl) phenyl) acetamide of formula (1).

The present invention relates to a process for preparing substituted acrylic acid ester and the use thereof to prepare (S)-3-(aminomethyl)-5-methylhexanoic acid generically known as pregabalin.

See attached

Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of Rilpivirine or a pharmaceutically acceptable salt. The present invention also provides an improved process for the preparation of Rilpivirine intermediate.

The present invention provides a novel process for crystallization of metaxalone from mixture of acetonitrile-water.

The present invention provides a novel process for preparation of flupirtine maleate (2) comprising the steps: (a) reduction of 2-amino-3-nitro-6-[(4-flurobenzyl)amino] pyridine (5) using Raney Ni and hydrazine hydrate to give 2,3-diamino-6-[(4-flurobenzyl)amino] pyridine (6), (b) ethoxycarbonylation of compound ...

NONE

The present invention relates in general to a process of production of recombinant heterologous proteins in E. coli expression system using E. coli Yeast fungi or mammalian methionine amino peptidase (MAP) protein as a fusion tag. Further the invention relates to the fusion proteins of MAP protein. ...

The present invention relates to a process for the preparation of Lacosamide. The present invention also relates to novel intermediates and their use in the preparation of Lacosamide.

NONE

NA

The invention proposes a rocker carrier having at least one operating rocker (1) of a door station or residence station of a home communication system, • having a linear guide between at least one guide dome (2, 3) of the operating rocker (1) and at least one linear guide (14, 15) of the rocker carrier, • having a...

NONE

12345Disclosed is a compound of formula (I) wherein R R R R R and m are as described herein as a modulator of nicotinic acetylcholine receptors particularly a7 subtype its tautomeric forms its stereoisomers its pharmaceutically acceptable salts its pharmaceutical composition and its combinations with suitable medica...

The present invention relates to process for the preparation of methylprednisolone sodium succinate and its purification by using crystallization method. The present invention also relates to novel polymorph of methylprednisolone hemisuccinate and its preparation.

The invention is directed to a process for the preparation of canagliflozin. The invention further comprises novel intermediate compounds and method of preparing the same, which are useful in the preparation of canagliflozin. The invention is further directed to a process for the preparation of amorphous form of can...

The present invention provides an improved process for preparation of an intermediate of apremilast, which is cost-effective, robust, and viable at plant scale.

The present invention relates to the stable pharmaceutical compositions comprising tumor necrosis factor receptor Fc fusion protein (TNFR:Fc). More particularly it relates to the stable pharmaceutical compositions comprising tumor necrosis factor receptor Fc fusion protein (TNFR:Fc) phosphate  citrate buffer. It als...

The present invention provides co-crystals of gatifloxacin (I) with a co-crystal former and process for preparation thereof. Co-crystal former is selected from oxalic acid, citric acid, DL-tartaric acid, glutaric acid, succinic acid, fumaric acid, malonic acid, salicylic acid and hydroxy benzoic acid. ...

The present invention relates to the stable pharmaceutical compositions comprising PEG interferon alpha 2b. More particularly it relates to the stable pharmaceutical compositions comprising PEG interferon alpha 2b and cryoprotectant selected from the group consisting of 2 Hydroxy propyl beta cyclodextrin sucralose o...

The present invention is directed to polymorphic forms of Pitavastatin tert-butyl amine salt and processes for preparation of the same.

The present invention relates to process for preparation of ledipasvir of formula 1 and its novel intermediates. The process involves reacting a compound of formula 4 with compound of formula 5 to yield a compound of formula 3, deprotecting a compound of formula 3 to yield compound of formula 2 and converting a comp...

This invention provides novel polymorphs of apremilast. This invention also provides a process for preparation of novel polymorphs of apremilast, which are cost-effective, robust, and viable at plant scale. The present invention also provides pharmaceutical compositions of novel polymorphs of apremilast. ...

The present invention provides one pot process for preparation of highly pure unsaturated cinacalcet hydrochloride (II) comprising: i) converting 3-(trifluromethyl) cinnamic acid (III) into 3-(3-(trifluoromethyl)phenyl)prop-2-en-1-ol (IV), ii) converting 3-(3-(trifluoromethyl)phenyl)prop-2-en-1-ol (IV) to compound...

A process for preparation of 6a, 9a-difluro-11ß-hydroxy-16a-methyl-17a- propionyloxy-3-oxo-androsta-1,4-diene-17ß-carbothioic acid (referred as thioacid, III) by reacting the corresponding thioanhydride (II) with piperidine in ester solvent. Further the present invention provides a process for purification of thio...

The present invention provides novel crystalline form A of dolutegravir sodium with characteristic diffraction peaks at 6.3°, 7.8°, 9.3°, 11.4°, 12.4°, 13.5°, 12.7°, 15.1°, 15.8°, 18.3°, 19.0°, 19.6°, 20.7°, 22.8°, 23.1°, 24.3° and 25.8° ± 0.2 degree two theta in an X-ray diffraction pattern. The present invention f...

The invention relates to stable oral pharmaceutical compositions comprising lanthanum carbonate compounds and pharmaceutically acceptable excipients. The compositions of the present invention are formulated without the use of flow aids or lubricants. The compositions of the present invention have physical properties...

See Attachment

The present invention provides new novel forms of Vortioxetine hydrobromide namely Form L of crystalline vortioxetine hydrobromide and tert-amyl alcohol solvate form of crystalline vortioxetine hydrobromide, process for their preparation and pharmaceutical composition thereof.

The present invention provides calcium sensing receptor modulators (CaSR). In particular the compounds described herein are useful for treating managing and/or lessening the severity of diseases disorders syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention al...

The present invention provides novel crystalline form L1 of daclatasvir dihydrochloride characterized by diffraction peaks at 5.35, 6.04, 6.76, 8.65, 9.21, 10.35, 10.32, 10.75, 11.04, 11.66, 12.95, 13.56, 16.06, 18.11, 20.58, 22.18, 23.27 ± 0.2 degree two theta in an X-ray diffraction pattern. The present invention ...

An improved, commercially viable and industrially advantageous process for the preparation of a prostaglandin derivatives and intermediates thereof, in high yield and purity, is provided.

Provided is a process of preparation of 2-[trans-4-(4"-chlorophenyl)cyclohexyl]-3- hydroxy-1,4-naphthoquinone, i.e. Atovaquone [I] which is cost effective, green, and eco-friendly process, without separation of any diastereomers or geometric isomers of intermediates obtained during the reactions. Also provided is...

Disclosed is a compound of formula (I) wherein Y Ring D m and R R are as described herein as a modulator of nicotinic acetylcholine receptors particularly the a7 subtype in a subject in need thereof as well as pharmaceutically acceptable salts polymorphs solvates and isomers thereofs for use either alone or in combi...

The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of Formula (I) their pharmaceutically acceptable salts combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation...

The present invention is related to heteroaryl comounds as MEK inhibitors. The invention includes heteroaryl compounds of formula I their tautomers and pharmaceutically acceptable salts combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of prepa...

The present invention is directed to substantially pure amorphous forms (L1 and L2) of Simeprevir sodium salt, process for the preparation and pharmaceutical composition thereof.

The present invention relates to compounds of Formula (I) that are useful for treating preventing and/or managing the diseases disorders syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds pharmaceutical compos...

The present invention provides an improved process for preparation of testosterone (I) by dealkylation of 3-enol ether (III) with aqueous formic acid.

1234567Disclosed is a compound of formula (I) wherein R R R R R R R and m are as described herein as a modulator of nicotinic acetylcholine receptors particularly a7 subtype its tautomeric forms its stereoisomers its pharmaceutically acceptable salts its pharmaceutical composition and its combinations with suitable ...

The present invention relates to a process for preparation of substantially pure Vilazodone Hydrochloride and also relates to an isolated impurity of Vilazodone. The said process for producing Vilazodone, 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbonyl benzofuran-5-yl) piperazine represented by formula (1) or a pharma...

see attached

A polymorph of emtricitabine, wherein said polymorph displays angular positions of characteristic peaks in powder X-ray diffraction pattern 13.61± 0.2, 15.54± 0.2, 19.49± 0.2, 20.55± 0.2, 25.89± 0.2, 28.09± 0.2 and 29.10± 0.2. A pharmaceutical composition comprising a polymorph of emtricitabine displaying angular...

The present invention provides compound of formula III and compound of formula IV and process for preparation thereof, III IV wherein, P is hydroxy protecting group; R1 is –CHO, –CH(OR2)(OR3), –CH(OH)CH2OH or –CH=CH2; R2 and R3 are H or lower alkyl; R4 is -N(R5)2, or –OR5; R5 is lower alkyl; and ...

The present invention provides a process of preparation of an intermediate useful for the preparation of statins more particularly the present invention relates to an eco-friendly and cost effective process for the preparation of tert-butyl (3R,5S)-6-oxo-3,5-dihydroxy-3,5-0-isopropylidene-hexanoate [I]. ...

The present invention provides a process for the preparation of enantiomerically pure (R)-1-(1-naphthyl)ethylamine of formula (IIa) by treating 1-acetylnaphthalene of formula (I) with R-selective transaminase enzyme in presence of amino donor. The (R)-1-(1-naphthyl)ethylamine of formula (IIa) thus obtained is furth...

The present invention provides a process for the purification of norethindrone acetate (II) from organic solvents or mixture of organic solvents.

The present invention relates to novel, industrially feasible process for preparation of pure sulfoxide compounds.

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof which modulate the activity of calcium release activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds ther...

The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof which modulate the activity of calcium release activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I)and pharmaceutical compositions containing such compounds there...

The present invention provides a process for the preparation of amorphous form of selexipag (Ia). The present invention also provides a novel amorphous form of selexipag sodium (Ib) and selexipag potassium (Ic) and methods for preparing the same. Further, the present invention also provides a solid dispersion of amo...

A ternary co-crystal consisting of 1:0.5:0.5 molar proportion of (S)-1,1'-bi-2-naphthol, 3(S)-propyl-4-[(S)1'-phenyl-ethylamino]-butanoic acid and 3(R)-propyl-4-[(S)1'-phenyl- ethylamino]-butanoic acid having characteristic powder X-ray diffraction pattern with 2θ values of 8.41, 9.38, 10.32, 12.16, 15.52, 15.51,...

The present invention provides purification of drospirenone by column chromatography over basic alumina and elution with tetrahydrofuran. The present invention further relates to a process for crystallization of drospirenone from dimethylformamide-water mixture.

The present invention is related to pyrrole derivatives of formula I as the modulators of nicotinic acetylcholine receptors particularly the a7 subtype. The invention includes pyrrole derivatives analogues their prodrugs their isotopes their metabolites pharmaceutically acceptable salts polymorphs solvates optical i...

Disclosed is a compound of formula (I) wherein Z m and R R are as described herein as a modulator of nicotinic acetylcholine receptors particularly the a7 subtype in a subject in need thereof as well as analogues prodrugs isotopically substituted analogs metabolites pharmaceutically acceptable salts polymorphs solva...

A multiple unit tablet composition comprising an enteric coated multiple unit cores comprising a pharmaceutically active ingredient, wherein plasticizer content of enteric coating is less than about 10% by weight of the enteric coating polymer; atleast two diluents and optionally one or more other pharmaceuticall...

The present invention provides a novel process for the preparation of Sofosbuvir and its intermediates. The process comprises generation of compound of formula 3 and its deprotection to obtain Sofosbuvir.

The present invention provides a process for preparation of threo-3-(3,4-dihydroxyphenyl)serine derivative substantially free of erythro-3-(3,4-dihydroxyphenyl)serine derivative by condensing 3-(3,4-dihydroxyphenyl)-benzaldehyde derivative with glycine in presence of base in organic solvent under substantially anhyd...

The present invention relates to a pharmaceutical composition comprising Cefditoren pivoxil, water soluble high molecular weight substance and one or more pharmaceutically acceptable excipient wherein weight ratio of high molecular weight substance to Cefditoren pivoxil is greater than 1: 4 and a process for prep...

SEE ATTACHED

The present invention relates to pharmaceutical compositions of Proton Pump Inhibitor and process for preparation of such composition thereof. The invention relates to pharmaceutical compositions comprising Proton Pump Inhibitor, crospovidone, basic inorganic salt and one or more pharmaceutically acceptable excipien...

A process for preparation of 2-(4-(4-chlorophenyl) cyclohex-1-enyl)-3,4-dihydronaphthalen-1(2H)-one (V), key intermediate for synthesis of Atovaquone [I] . The process for preparation of compound(V) [V] comprising of the steps of; i) Reaction of 2-(4-(4-chlorophenyl)-1-hydroxycyclohexyl)-3,4-dihydronaphthal...

Compounds of Formula (I) along with processes for their preparation that are useful for treating managing and/or lessening the diseases disorders syndromes or conditions associated with the modulation of calcium sensing (Ca SR) receptors. Methods of treating managing and/or lessening the diseases disorders syndromes...

The present invention relates to a process for the preparation of amorphous canagliflozin. The present invention also relates to a process for the preparation of canagliflozin.

The present invention provides novel process for preparation of olmesartan medoxomil (I) substantially free of olmesartan acid impurity (II) comprising, reacting trityl olmesartan medoxomil (III) with acid, filtering the precipitate of trityl alcohol, subjecting the filtrate to agitated thin film drying and recoveri...

The present invention relates to an improved process for the preparation of compound of formula (VII): which is useful as an intermediate for the preparation of Simeprevir or pharmaceutical acceptable salt thereof. The improved process parameters include using particular molar ratio of sodium hydroxide base and...

The present invention provides aprocess for the preparation of lopinavir intermediate (2S,3S,5S)-2-Amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2- onyl)-3-methyl butanoyl]amino-l,6-diphenylhexane (S)-Pyroglutamic acid salt(II) comprising: (a) N-debenzylation of (2S,3S,5S)-2-N,N-dibenzylamino-3-hydroxy- 5-[2S-(l-t...

Disclosed herein an improved process for preparing (±)-cis sertraline and its pharmaceutically acceptable acid addition salt thereof comprising hydrogenation of 4-(3,4-dichlorophenyl)-3,4-dihydro-N-methyl-1- naphthalenimine by using chiral ligand (S)(+)-BIQOL PA to obtain (±)-cis sertraline as pure product. ...

The present invention relates to a process for purification of 4-androsten-3,17-dione (II) and its conversion to testosterone (I) having purity > 99 % as measured by HPLC.

The invention describes novel crystalline forms of Tedizolid phosphate designated as L1, L2, and L3 and processes for the preparation thereof. The invention also describes amorphous form, stable amorphous premix of Tedizold Phosphate designated as L4, L5 respectively, and processes for the preparation thereof. ...

The present invention provides an improved process for the preparation of N-(2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide (Raltegravir) or a pharmaceutically acceptable salt thereof via amine salt of 2-(l -amino-1 -methylethy...

see attachment

See Attachment

Disclosed is a compound of formula (I) wherein a and R R are as described herein as a modulator of nicotinic acetylcholine receptors particularly the a7 subtype in a subject in need thereof as well as analogues prodrugs isotopically substituted analogs metabolites pharmaceutically acceptable salts polymorphs solvate...

A dry taste masked powder composition comprising a steroid or its salts or derivatives and pharmaceutically acceptable excipients. The taste masked powder may be used for suspension compositions suitable for use as a liquid suspension for children and elderly patients.

See Attachment

The present invention relates to controlled release formulation of dronedarone of pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of controlled release formulations of Dronedarone would improve the bioavailability and the patient com...

NONE

SEE ATTACHED

The present invention is directed to substantially pure stable solid dispersion comprising amorphous Vilazodone Hydrochloride, 5-[4-[4-(5-cyano-lH-indol-3-yl) butyl]-l-piperazinyl]-2- benzofuran carboxamide hydrochloride of formula 1a and a pharmaceutically acceptable water soluble polymer and process for preparatio...

A process for preparation of enantiomerically enriched and/or racemic γ-amino acids particularly those useful for preparing γ-amino acids that exhibit binding affinity to the human α2δ calcium channel subunit including pregabalin and related compounds such as 3-«-propyl-4-aminobutyric acid.

The present invention is related to a novel process for the preparation of ulipristal (I) that comprises reaction of 17-α-ethynyl-17-β-hydroxy-11-β-(4-N,N-dimethylamino phenyl)- 19-norpregna-4,9-diene-3-one (III) with phenyl sulphenyl chloride (IVa) or p-nitro phenyl sulphenyl chloride (IVb) in the presence of or...

Disclosed are an alpha 7 nAChR receptor modulator compound 4 (5 (4 chlorophenyl) 2 (2 cyclopropylacetyl) 1 4 dimethyl lH pyrrol 3 yljbenzenesulfonamide its tautomeric form its pharmaceutically acceptable salts pharmaceutical compositions comprising the compound or a salt thereof and a method of treating various dise...

The present invention provides a stable, organoleptically acceptable topical formulation(s) of the tetracycline antibiotics or pharmaceutically acceptable salts or hydrates thereof for the treatment of acne.

The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts wherein the substituents are as described herein and their use in medicine for the treatment of diseases disorders associated with the modulation of calcium release activated calcium (CRAC) channel. The invention also relat...

1234567Disclosed are compounds of the formula (I) wherein R R R R R R R and m are as described herein as modulators of the nicotinic acetylcholine receptors particularly the a7 subtype their tautomeric forms stereoisomers and their pharmaceutically acceptable salts pharmaceutical compositions thereof and combination...

This invention provides a novel solvate of darunavir i.e darunavir n-propanol solvate. This invention also provides a process for preparation of darunavir n-propanol solvate, which is cost-effective, robust, and viable at plant scale. The present invention also provides pharmaceutical compositions of darunavir n-pro...

The invention is related to high cell density fermentation process for production of heterologous proteins in E. coli expression system. The invention is also related to the process for the production of heterologous proteins in E. coli using pBAD24T7g10 vector. The invention is also related to the vector pBAD24T7g1...

NONE

An improved process for the preparation of 7-amino-3-(4-methylthiazol-5-yl) vinyl-3- cephem-4-carboxylic acid [7-ATCA]; an intermediate used in the synthesis of cefditoren pivoxil with a high purity.

This invention describes processes for preparation of Form II of apremilast. Particularly, these processes for Form II of apremilast are viable and stable at plant scale.

The present invention provides improved process for preparation of revaprazan hydrochloride (I) comprising reaction of 1-methyl-1,2,3,4-tetrahydroisoquinoline (III) withcompound (VII)wherein R is a good leaving group selected from F, Cl, Br, I, in presence of phase transfer catalyst and solvent to give revaprazan...

A novel process for racemization of (R)-3-cyano-5-methyl hexanoic acid ethyl ester directly to (RS)-3-cyano-5-methyl hexanoic acid has been developed through a base catalyzed mechanism in a specific solvent system.

Improved process for the synthesis of (S)-pregabalin having more than 99% ee through (S) - 3-cyano-5-methyl-hexanoic acid has been developed. In addition to above, a novel process for resolution of (RS) - 3-cyano-5-methyl-hexanoic acid through diastereomeric salt formation with cinchonidine to obtain (S) - 3-cyan...

The invention relates to process for purification of recombinant human IL 1 1 from microbial cells. The method involves purification using hydrophobic interaction chromatography and ion exchange chromatography. The method further comprises use one or more fusion tags which provides solubility to the protein and also...

The present invention relates in general to a process of production of recombinant heterologous proteins using fusion proteins of truncated E. coli thioredoxin. Further the invention relates to the fusion proteins of truncated thioredoxin to increase the production activity stability or solubility of recombinant het...

The present invention relates to modified SAK gene having amino acid SEQ ID 2. The present invention further relates to process for cloning and expressing modified SAK gene fusion protein which imparts improved stability to the heterologous protein of interest. Further the invention relates to process of purificatio...

The present invention relates to controlled release pharmaceutical compositions comprising Brivaracetam or its pharmaceutically acceptable derivatives thereof. Further disclosed is a controlled release pharmaceutical composition comprising a core and a coating surrounding the core wherein the core comprises Brivarac...

A stable liquid oral pharmaceutical composition comprising montelukast, a vehicle comprising mineral oil, desiccant and optionally pharmaceutically acceptable additives is provided. The invention also relates to kit for dispensing of oral pharmaceutical compositions of Montelukast. The kit comprises montelukast, ...

A novel process for racemization of (S)-3-carbamoylmethyl-5-methyl-hexanoic acid to 3-carbamoylmethyl-5-methyl-hexanoic acid racemate has been developed.

A novel crystalline anhydrous polymorph of armodafinil having XRD peaks at 6.6, 10.4, 13.3, 14.0, 16.5, 17.4, 17.7, 19.0, 19.4, 20.0, 20.8, 21.1, 21.4,22.3, 22.8, 23.5, 25.6, 26.0, 26.0, 26.8, 27.6, 28.3, 28.6, 29.1, 29.8, 31.9, 34.3, 35.2, 39.3 ± 0.2 degrees 2-theta and a process for preparation of novel anhydro...

An engine with the attached axial gap type rotating electric machine includes a crank case, a rotor, and a stator. A crank shaft, that is driven to rotate around a center axis by a piston, is inserted within the crank case such the crank shaft can rotate. The rotor is fixed to an end section side of the crank shaft ...

Pharmaceutical composition of Trimetazidine or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof using dual retard release technique. A once daily sustained release pharmaceutical composition comprising a core comprising trimetazidine or a pharmaceutically acceptable ...

See Attachment

NONE

NONE

The present invention is directed towards a controlled release oral pharmaceutical dosage form comprising as an active ingredient metformin or its pharmaceutically acceptable salts and controlled release excipient. The formulation of the present invention provides controlled release of metformin hydrochloride wit...

The present invention relates to a novel process for the preparation of zopiclone (1) that involves the reaction of 6-(5-chloropyridin-2-yl)-5-hydroxy-7-oxo-5,6- dihydropyrrolo[3,4-b]pyrazine-5-one (5-OH-Py) (3) with chloro-carbonyl-4-methyl- piperazine (CMP) free base (4) or as an acid addition salt in the prese...

A pharmaceutical composition comprising minocycline or its salts and one or more polymers selected from the group comprising of polyalkyleneoxide, alginic acid or its salts and one or more pharmaceutically acceptable carriers.

A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more...

The present invention relates to a novel method for obtaining (2S, 3aS, 6aS)-1- [(S)-2-[(S)Ethoxybonyl)-3-phenypropyul]amkino] propanoyl] octahydro cycleopenta[b]pyrrole-in ghigh bulk density. The presetn invention also relates to a novel hydrated form of Ramipril (I) and a proceess for preparation thereof. ...

A novel oral controlled release pharmaceutical composition comprising a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt thereof, one or more controlled release agents(s) selected from pH independent polymers, water insoluble substances and combination thereof, and pharmaceuticall...

A stable solid oral pharmaceutical composition comprising carvedilol or a pharmaceutically acceptable salt thereof, which is packed using a suitable packaging material along with a desiccant. A process for manufacturing a stable solid oral dosage form containing carvedilol or a pharmaceutically acceptable salt there...

The invention relates to a compound of formula II and a process for its synthesis from 4-[2-(5-methylpyrazine-2- carboxamido)ethyl]benzene sulfonamide. The invention also relates to a process for preparing Glipizide wherein the compound of Formula II acts as an intermediate.

A novel reduced dose pharmaceutical composition comprising combination of fexofenadine or salts thereof; and pseudoephedrine or salts thereof in therapeutically effective amount, for the treatment of allergic rhinitis and associated symptoms in pediatric population.

An Improved Process For The Synthesis Of 10-Dihydro-10-Deoxo-ll-Azaerythromycin A The present invention relates to an improved process for preparing 10-dihydro-10-deoxo-11-azaerythromycin A of the formula I from its precursor iminoether of formula II by catalytic hydrogenation in presence of polyhalogenated alkanes...

Quinapril tris salt having distinct X-ray diffraction peaks at 20 of 3.80, 7.57, 8.60, 9.33, 9.46, 11.35, 14.11, 14.38, 14.78, 15.16, 16.17, 17.16, 17.59, 17.74, 18.23, 18.96, 20.14, 20.34, 20.68, 20.86, 22.49, 22.74, 23.24, 23.81, 24.56, 25.24, 26.17, 26.67, 26.93, 28.53± 0.2°. Ramipril tris salt having distinct...

ABSTRACT IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE TRANDOLAPRIL The present invention provides an improved process for preparation of highly pure trandolapril. The process comprises of the following steps: (i) crystallization of mixture of racemic benzyl trans- (2S, 3aR, 7aS)- octahydro-1H-indole carboxylat...

The present invention relates to a novel process for the preparation zileuton (1) involving the steps of: i) preparation of 2-acetylbenzo[b]thiophene oxime (3) by reacting 2- acetylbenzo[b]thiophene (2) with hydroxylamine hydrochloride; ii) reduction of the 2-acetylbenzo[b]thiophene oxime (3) with organotinhydri...

A delayed release dosage form comprising core comprising duloxetine or its pharmaceutically acceptable salts or derivatives thereof, optionally, other pharmaceutically acceptable excipient(s) thereof; intermediate layer; and enteric layer; wherein the dosage form comprises one/more dissolution enhancer(s), wherei...

N/A

A process for manufacture of amorphous Rabeprazole sodium with mean partical diameter between 10 to 55 um said process comprising addition of Rabeprazole to aquenous sodium hydroxide; addition of ethyl alcohol to the solution; distillation of solvents from the solution thus obtained till thick mass is obtained; addi...

An improved stable pharmaceutical composition for controlled release of an active ingredient comprises a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters as active ingredient, a calcium salt and a mixture of hydrophilic polymers selected from the group...

A method for the manufacture of Lovastatin of formula (I) is disclosed. The method comprises of : A. lactonisation of Mevinolinic acid (II) and isolation of impure Lovastatin (I), B purification of impure Lovastatin (I), C optionally repurification of pure Lovastatin (I) from a mixture of alumina and a water miscibl...

Oral pharmaceutical compositions if cephalosporins, particularly Cefpodoxime, a process for preparing the same and a method for enhancing the stability of these oral pharmaceutical compositions. The oral pharmaceutical composition of a cephalosporin is stable and has adequate bio - availability, and comprises the ce...

A process for the polymerization of allylamine and its subsequent crosslinking in the presence of a dispersing agent.

A stable modified release preparation having single coated core elements, each core element comprising an active ingredient selected from the group consisting of the acid salts of doxycycline, trospium, tetracycline, oxytetracycline, minocycline, chlortetracycline or demeclocycline and having a modified release co...

A pharmaceutical suspension formulation comprising a dose greater than 100 mg /5ml Cefixime and pharmaceutically acceptable excipients.

A controlled release pharmaceutical composition(s) comprising choline fenofibrate wherein the core comprises choline fenofibrate and auxiliary excipient and a coating layer comprising rate controlling agent(s). A controlled release pharmaceutical composition(s) comprising choline fenofibrate comprising an immedia...

The present invention provides a novel process for preparation of 6-fluoro-3,4-dihydro-2(H)-benzopyran-2-carboxaldehyde (2) comprising the steps of: 1. esterification of 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid (4) to obtain ester (7), 2. reduction of ester (7) to afford 6-fluoro-3,4-dihydro-2H-1-ben...

Process for the preparation of amorphous atorvastain calcium. A solution of atorvastatin calcium in a solvent selected from the group consisting of halogenated aliphatic hydrocarbon, dimethyl formamide, dimethyl formide, dimethyl acetamide, acetic acid is added to any anti-solvent and the solution is concentrated to...

An improved process for the preparation of crystalline ziprasidone base comprising dissolving ziprasidone in tetrahydrofuran by heating to reflux, treating the reaction mass with activated charcoal, adding methanol to the reaction mass, and isolating crystalline ziprasidone base.

A proces for the preparation of valsartan of formula (I)of at least 98% enantiomeric purity comprising preparing a novel oxalate salt of the formula (IIa), converting the compound of formula (IIa)to valsartan of formula (I), and isolating valsartan of formula (I) in an amorphous form. The invention also relates to ...

A process is provided for the preparation of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof which comprises of: (a) reacting 4-aminobutyric acid with a mixture of phosphorous acid and phosphorous trichloride in solvent selected from sulfolane, diglyme and diphenyl oxide (b) hydrolyzing the resul...

The present invention relates to novel crystalline form D of varenicline L-tartarate and process for its preparation that involves crystallization from acetonitrile-water mixture.

The present invention relates to a water drainable and permeable drainage system and method for treatment of soft ground, which enable surface layer treatment of soft ground by installing open channels and collector wells of water drainable and permeable members on soft ground to drain surface water and subsurface s...

An orally disintegrating pharmaceutical composition comprising Escitalopram or salts thereof as an active ingredient; diluent (s) selected from the group consisting of cellulose derivatives such as microcrystalline cellulose and the like, mannitol, lactose, dextrose, sorbitol, starch, xylitol, maltose, dicalcium ...

A pharmaceutical formulation of active principles for gastrointestinal drug delivery that comprises an mucoadhesion site-controlling layer for attaching the formulation to the selected site in the digestive tract. The pharmaceutical composition, comprises a therapeutically effective amount of active principle(s) ...

A pharmaceutical composition comprising a therapeutically effective amount of rifaximin or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s), optionally one or more controlled release agent(s) and solubilizing agents thereof, wherein the composition is...

Title: PROCESS FOR THE PREPARATION OF OPTICALLY PURE OR OPTICALLY ENRICHED ENANTIOMERS OF SULPHOXIDE COMPOUNDS A process for preparation of optically pure or optically enriched enantiomers of sulphoxide compounds of formula (I), such as omeprazole and structurally related compounds, as well as their salts and hydr...

The present invention relates to a novel polymorph of O-desmethylvenlafaxine glutarate and process for preparing the same thereof.

The present invention provides a stable amorphous form of carvedilol dihydrogen phosphate and process for its preparation. The process for the preparation of stable amorphous form of carvedilol dihydrogen phosphate comprises of: (a) preparation of a solution of carvedilol base in a suitable solvent or mixture of so...

A taste masked pharmaceutical composition of clindamycin, or a pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof, which includes all polymorphic forms, whether crystalline or amorphous comprising polyhydric alcohol(s); and one or more o...

An improved process for the synthesis of various intermediates useful in the synthesis of Dipeptidyl peptidase (DPPIV) inhibitors. The present invention relates to an improved process for the preparation of a key intermediate viz. methyl (2S)-2-(tert-butoxycarbonyl)- amino-2-[-8-azabicyclo[3.2.1]oct-3-yl]-exo-ace...

An improved, safer and easy to operate on plant scale process for synthesis of duloxetine hydrochloride (1) having chiral purity greater than 99.9% that is characterized by the following: (i) preparation of racemic condensed compound (RS)-N,N-di methyl-3- (1- naphthyloxy)-3-(2-thienyl)propanamine (4) by reaction o...

The present invention relates to a novel method for obtaining (2S,3aS,6aS)-l-{(S)-2-[[(S)- I -(ethoxycarbonyl)-3 -phenyipropyl] -amino] propanoyl] octahydro cyclopenta[b] pyrrole2-carboxylic acid, viz. Ramipril(I) in high optical purity, free of other stereoisomers, and in high bulk density. The present invention ...

The present invention relates to a colon targeted modified release bioadhesive pharmaceutical composition of 5-amino salicylic acid or a pharmaceutically acceptable salt or enantiomer or polymorph or metabolites thereof, optionally one or more hydrophilic or hydrophobic release controlling agent(s) and pharmaceutic...

The present invention relates to sustained release dosage form of Ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof which comprises a combination of atleast two pH-dependent binders and optionally one or more pharmaceutically acceptable excipient(s). ...

A modified vector prepared by ligating a reporter gene having a STOP codon upstream of the multiple cloning site of the vector. A method for identification and screening of recombinant clone comprising the gene of interest wherein the method involves the replacing the multiple cloning site and the STOP codon in t...

The invention relates to Form IV of Levetiracetam characterized by an XRD pattern as depicted in Figure 1 and a process for its preparation.

An orally administrable pharmaceutical dosage form for the prevention and treatment of cardiovascular disorders, comprising a cholesterol-lowering agent, an inhibitor of the peroxisome proliferator activator agent and aspirin; along with at least one pharmaceutically acceptable excepient. . An orally administrable p...

The present invention relates to a method of reducing the incidence of nausea and vomiting associated with the administration of oral contraceptive formulation and a method of preparation of oral contraceptive formulation comprising progestin and /or estrogen and an antiemetic. The preferred oral contraceptive fo...

A controlled release pharmaceutical composition containing a core comprising tolterodine or pharmaceutically acceptable salts and auxiliary excipients and a single coating layer comprising rate controlling agents(s). A controlled release pharmaceutical composition comprising tolterodine or pharmaceutically acceptabl...

The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs. ...

A controlled release pharmaceutical composition which comprises therapeutically effective amount of pregabalin or salts thereof as active ingredient, a hydrophobic release controlling agent(s) and optionally other pharmaceutically acceptable excipients thereof.

The present invention relates to novel processes for the preparation of zileuton (I). The present invention further relates to novel anhydrous crystalline form of zileuton and process for its preparation.

An improved method for preparing a compound of formula (I) which comprises of coupling the piperazine derivative of formula (II) with oxindole derivative of formula (III) by heating in a non-aqueous medium, in the absence of an external base and optionally in presence of a catalyst.

A dicyclohexyamine salt of compound of formula I, namely perindopril, having an X-ray powder diffraction pattern with characteristic peaks (2θ): 8.462, 10.624, 18.693, 9.424, 17.272, 14.177, 19.499, 20.765, 21.409, and 14.540. A process for preparation of the said salt of perindopril and its use in the purification...

The present invention provides a novel anhydrous crystalline form of carvedilol dihydrogen phosphate referred to as Form A having water content below 1.3%. Further it provides a process for the preparation of Form A. The PXRD, FT-IR and TGA data has been provided.

A stable pharmaceutical composition consisting of (a) benazepril, in free or pharmaceutically acceptable salt form; and (b) amlodipine, in free or pharmaceutically acceptable form. The composition is free of alkaline earth metal carbonates and phosphates. The composition is also free of excipients which increase the...

An antimycobacterial combination and composition for treating tuberculosis are described. The Compounds used are N-(3-[[4-(3-trifluoremethylphenyl) piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxiamide of formula (1) or a pharmaceutically acceptable non-toxic salt thereof and an amount of one or more...

Novel pyrrole derivatives of formula (I), and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis as well as having lesser toxicity compared to known compounds. The use of the novel co...

The present invention relates to a novel process for the preparation of clopidogrel bisulfate (1) that comprises preparation of alpha bromo (2-chloro) phenyl acetic acid (VII) by treatment of 2-chloro phenyl acetic acid (VI) with N-bromo succinimide in the presence of a radical initiator and using dialkyl carbona...

A slow release pharmaceutical composition comprising iloperidone or its active metabolites and a slow release agent is described. Also disclosed is slow release pharmaceutical composition comprising iloperidone or its active metabolites, wherein the slow release composition is a combination of a controlled release c...

Thermal spray alloy coated BOF stack tubes panels directed to improved performance and extended operational life. More particularly, the thermal spray coating process is directed to providing selective alloy composition and optimized spray parameters to protect the BOF stack tubes from erosion and corrosion of tu...

The process of the present invention relates to a method for the synthesis of a 1,4- diphenylazetidinone of formula (VIII) by using novel oxime intermediates.

An expandable drug delivery system comprising of one or more actives, force generating components, optionally containing one or more absorption modifiers

An oral pharmaceutical composition, which comprises one or more positively charged, highly water soluble pharmaceutically active agents, and one or more material substance containing non-polarized oxygen atoms, in a manner such that the active agents will not form any sort of interaction with the polymer(s). ...

A novel controlled release pharmaceutical dosage form comprising a therapeutically effective amount of ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof, one or more lipid(s) as release controlling agent(s) and one or more pharmaceutically acceptable excip...

The present invention describes a novel process for large-scale purification of therapeutic grade quality of recombinant human GCSF from microbial cells, wherein the protein is expressed as inclusion bodies. The Inclusion bodies are solubilized and refolded under redox condition. The Redox condition is provided by u...

An improved process for Efavirenz, which has several advantages over reported methods like low cost, high yield, better optical purity and industrial feasibility.

The present invention relates to novel process for preparation of varenicline. The invention also relates to novel amorphous form of varenicline L-tartarate, amorphous form of varenicline L-tartarate with povidone (PVPK 30) and process for their preparation.

A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90% of the total amount of Milnacipran or pharmaceutically acceptable salts thereof between 8 to 20 hours when dissolution is carr...

A controlled release oral pharmaceutical dosage form comprising (1) a core comprising an active ingredient metformin or its pharmaceutically acceptable salts, hydrophilic substance and/or hydrophobic substance (2) permeable coating, wherein the dosage form provides a mean time to maximum plasma concentration (Tma...

The present invention relates to an improved process for the preparation of 7-AVCA(1a)and for(Z)-isomer enriched 7-APCA(1b)by carrying out multi step reactions in one pot and utilizing sodium bromide in Wittig reaction.

The present invention provides amorphous form of carvedilol dihydrogen phosphate and processes for the preparation of it.

A process for the preparation of crystalline ziprasidone hydrochloride monohydrate of formula (I). Comprising dissolving ziprasidone base in an organic solvent selected from alkanols and ethers; adding a solution of hydrogen chloride dissolved in an organic solvent selected from alkanols and ethers; isolating the so...

The present invention provides an improved, safer and easy to operate on plant scale process for synthesis of duloxetine hydrochloride (1) that is characterized by: (i) preparation of racemic condensed compound (RS)-N,N-di methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine oxalate (4) by reaction of racemic hydroxy c...

A NOVEL PROCESS FOR PRAPARATION OF POLYMORPHIC FORM II OF SERTRALINE HYDROCHLORIDE A process for making sertraline hydrochloride form II, free from any other polymorph, comprises disolution of sertraline base or its mandelate salt in methyl isobuthyl ketone (MIBK), heating the solution to 60-65 0 c, addition of h...

PROCESS FOR PREPARATION OF BENZYL ESTER MALEATE SALT OF QUINAPRIL A process for preparation of a novel crystalline form of quinapril hydrochloride of formula(I). A process for preparation of amorphous form of quinapril hydrochloride, of high purity and conforming to pharmacopoeial specifications, by the use of...

A process for preparation of 4,5-Dihydroxy-9,10-dioxo-9,10-dihydro-anthracene-2- carbaldehyde from l,8-Dihydroxy-3-hydroxymethyl-anthraquinone comprising of aerial oxydation of l,8-Dihydroxy-3-hydroxymethyl-anthraquinone at oxygen pressure of about 1 to 2 bar in presence of a transition metal complex, a co-catalyst ...

The present invention provides novel anhydrous crystalline form designed as Form B of carvedilol dihydrogen phosphate and process for the preparation of it.

A chewable tablet dosage form comprising Cefdinir or pharmaceutically acceptable salts thereof for the oral administration of Cefdinir in a manner that is more palatable and less objectionable to population group's especially young children and older patients. A method of preparing the chewable tablets comprising Ce...

The present invention provides a novel process for preparation of darunavir that involves reduction of [( 1S,2R)-3-[[( 4-nitrophenyl)sulfonyl](2-methylpropyl)amino ]-2-hydroxy -1- (phenylmethyl) propyl] carbamic acid (3R,3aS,6aR)-hexahydrofuro [2,3-b]furan-3-yl ester, of formula (5). The present invention also pro...

An improved process for the manufacture of Lamivudine. The process involves preparation of racemic cis-(±)-Lamivudine of formula (XII), from a mixture of cis-(±) intermediate of Formula (IX) by forming a crystalline salt and separating the Cis-(±)-Lamivudine from an organic solvent by fractional crystallizat...

A novel process for the resolution of pregabalin by means of chiral acids. According to the process, racemic pregabalin is contacted with a chiral acid to precipitate a salt of the chiral acid with one of the enantiomer. The chiral acid for the purpose of the invention is selected from O, O-dibenzoyl-L-tartaric a...

A modified release pharmaceutical composition comprises a controlled release core comprising one or more selective serotonin reuptake inhibitor or pharmaceutically acceptable salts thereof, one or more controlled release agent(s) and pharmaceutically acceptable excipient(s), and one or more coatings comprising an...

A stable pharmaceutical composition comprising a non-lyophilized cephalsoporin antibiotic selected from ceftiofur sodium and cefotetan disodium and a pharmaceutically acceptable carrier. A process for the preparation of cephalosporin antibiotic comprises a) precipitating the cephalosporin antibiotic from a solution...

The present invention provides atazanavir sulfate substantially free of diastereomeric impurities. The present invention also provides atazanavir sulfate having D-tertiary leucine analogues less than 0.1%. The present invention further relates to an improved process for preparing atazanavir sulfate, substantially...

N/A

An antigen suspension comprising an antigen obtained by the steps of incubating a portion of M. tuberculosis wild strain growth in Sauton’s medium at 32 to 40ºC preferably 37ºC for 30 to 45 day till late log phase; collecting and dissolving the pellets there from in a solvent; inactivating the bacteria at 75 Cº to 8...

A process for prepartion of ceftriaxone sodium of formula(II), is disclosed the process comprising the steps of i 0 reacting a silylated compound of formula(III), with a 4-halo-2-methoxyimino-3-oxo-butyric acid derivative of formula (IV) wherein X and Y represent a halogen atom to give a compound of for...

A process for preparation of ceftiofur of formula (I) CT^-OH (I) of high purity and substantially free from impurities is disclosed. The process comprises reacting [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester of formula (II), H,N^ /S- with 7-amino-3-(...

N/A

The present invention relates to novel reagent 3-(S)-tetrahydrofuryl-1, 2, 4-triazole-1- carboxylate (III) useful in synthesis of fosamprenavir calcium. The present invention further relates to novel process for preparation of (3S)-tetrahydro-3-furyl N-[(1S,2R)- 1-benzyl-2-hydroxy-3-(N-isobutyl-4-nitrobenzenesulp...

A novel crystalline form B of carvedilol dihydrogen phosphate having X-ray diffraction pattern as shown in figure 1. A process for the preparation of crystalline form B of carvedilol dihydrogen phosphate according to claim 1 that comprises dissolving carvedilol base in aprotic polar solvent, addition of phosphori...

Accordingly, a major aspect of the present invention is to provide an improved process for the preparation of O-desmethyl venlafaxine from venlafaxine by O-demethylation of venlafaxine, which comprises reaction of venlafaxine with 1,2-ethanedithiol.

A kit for administration of emergency contraception comprising an oral contraceptive and an antiemetic, administered simultaneously or sequentially. A pharmaceutical combination comprising separate dosage forms, in a common package, of oral contraceptive and an anti-emetic useful in reducing nausea and vomiting a...

A crystalline form of pregabalin characterized by XRPD characteristic d spacing values at 9.27, 7.19, 4.66, 4.64, 4.47, 4.00, 3.82 and 3.77Å. The DSC thermogram shows characteristic peak at 201.28°C.

An oral controlled release pharmaceutical composition comprising a carvedilol or a pharmaceutically acceptable salt(s) thereof. The oral controlled release pharmaceutical composition comprises a core comprising a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt(s) thereof and/o...

A dicyclohexyamine salt of compound of formula I, namely perindopril, having an X-ray powder diffraction pattern with characteristic peaks (29): 8.462, 10.624, 18.693, 9.424, 17.272, 14.177, 19.499,20.765,21.409, and 14.540. COOH A process for preparation of the said salt of perindopril and its use in the purifica...

A proteolytic agent comprising a peptide, having autocatalytic property wherein said peptide is SAK protein. A proteolytic agent comprising an effective ingredient as a peptide consisting of DNA sequence corresponding to SAK gene, having autocatalytic property when exists as a fusion protein. A method for cloning an...

The present invention relates to a modified release dosage forms comprising cyclobenzaprine its pharmaceutically acceptable salts or derivatives and mixtures thereof and one or more release-controlling agent(s) and processes to prepare them. The invention is used to treat disorders involving skeletal muscle hyperton...

A process for the preparation of the pharmaceutical ingredient Diacerein, of Formula I, by oxidation of aloe-emodine, acylation of resulting Rhein followed by hydrolysis and final acetylation.

A three-durg antiretrovial pharmaceutical composition having a selective combination of a controlled release active formulation and an immediate release active formulation for once daily administration. The composition provides desired dosages of the actives lamivudine, zidovudine or pharmaceutically acceptable deri...

A Lethal gene called LG and a vector comprising the same as tool for zero background-cloning vehicles. The lethal gene is clonecd into the last restriction site in such a way that when any exogenous gene is inserted into the Multiple cloning sites (MCS) region upstream of the lethal gene, the expression of the letha...

The present invention provides a pharmaceutical composition/combination containing desvenlafaxine or its pharmaceutically acceptable form and one or more second active drug, wherein the said second active drug is selected from the group comprising of a compound that increases synthesis/ or release of monoamines, ...

An improved process for the crystallization of benazepril hydrochloride to obtain in at least 99.8% diastereomeric purity. The process comprises making a concentrated solution of benazepril hydrochloride in ethanol and adding the resulting solution to a non-solvent diisopropyl ether.

The disclosure herein relates to a new Lamivudine polymorphic form, methods of making the same, and pharmaceutical formulations thereof. A (-) cis-4-amino-1-(2-hydroxymethyl-l,3-oxathiolan-5-yl)-(lH)-pyrimidin-2-one in the form of monoclinic crystals has characteristic powder X-ray difractogram, as disclosed herein,...

NONE

The invention relates to process for the preparation of an inorganic acid addition salt of Sevelamer.

N/A

NA

NONE

See attached

See Attachment

A pharmaceutical suspension dosage form comprising greater than 80 mg/ml and not more than 150 mg/ml of Cefixime and pharmaceutically acceptable excipients.

Fusion tag comprising C terminus amino acids of human Granulocyte Macrophage Colony Simulating Factor (GM CSF), START codon and enterokinase cleavage site and adapted to express other wise non expressible genes. A process for formation of the fusion tag comprising amplification of C terminus 45 amino acids from a...

The present invention relates to a process for preparation of rosuvastatin and its pharmaceutically acceptable salts thereof. The invention also provides a novel intermediate and its use in preparation of rosuvastatin and its pharmaceutically acceptable salts thereof.

The present invention provides novel compounds of the general formula (I), wherein the symbols are same as described in specification, their pharmaceutically acceptable salts, their tautomeric forms, their stereoisomers, pharmaceutical compositions containing them, to process and intermediates for the preparation of...

Novel pyrrole derivatives of formula (I), and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis as well as having lesser toxicity compared to known compounds. The use of the novel co...

The present invention relates to an improved and novel process for preparation of ranolazine.

The present invention relates in general to a process of production of recombinant heterologous proteins in E. coli expression system using E. coli, Yeast, fungi or mammalian methionine amino peptidase (MAP) protein as a fusion tag. Further the invention relates to the fusion proteins of MAP protein. ...

Pharmaceutical ophthalmic compositions comprising active ingredient(s) such as carbonic anhydrase inhibitor (CAI) or combinations and processes for making such compositions and the use of these compositions in patient populations including pediatric populations. A process for preparing an ophthalmic composition comp...

NONE

NONE

An improved process for the synthesis of intermediates like Alkyl/Aralkyl (2S)-2-(tert-butoxycarbonyl)-amino-2-[-8-azabicyclo[3.2.1]oct-3-yl]-exo-acetate and analogs thereof which are useful in the synthesis of Dipeptidyl peptidase-IV (DPPIV) inhibitors.

See Attachment

Novel method for synthesis of optically pure (S) (-) 1 1 bi 2 naphthol and/or (R) (+) 1 1 bi 2 naphthol via resolution of racemic (RS) 1 1 bi 2 naphthol through formation of co crystal with optically active derivatives of γ amino acids.

The present invention providesa novel method to obtain olmesartan medoxomil (I) witha particle size distribution of less than 30 µm comprising: dissolving olmesartan medoxomil (I) in a solvent; adding seed crystals of olmesartan medoxomil (I), followed by isolation.

NO ABSTRACT

The present invention describes a novel crystalline form of imipramine hydrochloride, a novel crystalline form of imipramine pamoate and a novel amorphous form of imipramine pamoate Imipramine base was converted to imipramine hydrochloride by the addition of hydrochloric acid in organic solvent. Imipramine hydroc...

The present invention relates to pharmaceutical combinations of mesalamine or a pharmaceutically acceptable salt or prodrugs thereof and rifaximin or a pharmaceutically acceptable salt or prodrugs thereof to treat patients suffering from inflammatory bowel disease (IBD) and/or irritable bowel syndrome (IBS). The inv...

The present invention relates to a process for the preparation of asenapine maleate. The process of the present invention involves cyclization of 3-(5-chloro-2-phenoxyphenyl)-l-methylpyrrolidine-2,4-dione (II) to give ll-chloro-2-methyl-2,3-dihydro-lH-dibenzo[2,3:6,7]oxepino[4;5-C] pyrrol-1-one (III), reduction of c...

The present invention provides a novel process for the preparation of desogestrelof formula (I), comprising reaction ofll-methylene-18a-homo-estr-4-en-17-one (II) with acetylene gas in presence of potassium tertiary butoxide and ethylenediamine and in dioxane-dimethylacetamide mixture to give crude desogestrel. The ...

NONE

A controlled release dosage forms comprising zolpidem or a salt thereof to release zolpidem to induce rapid onset of sleep, and continue to release zolpidem in a controlled manner to maintain effective plasma concentrations over an extended period of time to improve sleep maintenance. The pharmaceutical controlled-r...

A pharmaceutical composition for extended release of erythromycin or a derivative thereof the composition comprises comprising a pharmaceutically effective amount of the drug and about 50% to about 65% by weight of one or more pharmaceutically acceptable polymer(s). The pharmaceutically acceptable polymer(s) are sel...

Process for preparation of compound of formula (I) by the reaction of compound of formula (III), with a solution of methylamine in water or in a mixture of water and a water miscible organic solvent at temperature between 30º C to 80º C and at atmospheric pressure. The solution of methylamine in water has a strength...

The present invention provides a process for preparation of atazanavir sulfate comprises reaction of atazanavir base with sulfuric acid in alcoholic solvent, partial removal of alcoholic solvent, addition of ketonic solvent and isolation.

YES

Compounds of Formula (I) along with processes for their preparation that are useful for treating managing and/or lessening the diseases disorders syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors. Methods of treating managing and/or lessening the diseases disorders syndromes ...

The invention relates to metal mediated synthesis of Deferasirox 4-[3,5-bis(2-hydroxyphenyl)-lH-l,2,4-traizol-lyl] benzoic acid, [I], an iron chelating agent, synthesized from 1, 2, 4-triazole. The process involves Preparation of 3,5-dibromo-lH-l,2,4-traizole (II) from 1,2,4 triazole; reaction of compound (II) with ...

A pharmaceutical composition for controlled drug delivery comprising a ß-lactam antibiotic or its pharmaceutically acceptable hydrates, salts or esters, and one or more carbomers. The above ß-lactam antibiotics formulation avoids the limitations of known ß-lactam controlled release form which are found to be either ...

A process for preparation of ceftiofur sodium of formula (lb) \ o^ * xOCH3 ° O \ (lb) possessing high stability and having purity of more than 97% and substantially free of impurities, is disclosed. The process comprises: i) reacting cefotaxime or its salts or its esters of formula (VI) O o H2N- N ^ ...

A novel crystaline form of quinapril hydrochloride of formula (I). An amorphous form of quinapril hydrocholride of high purity and conforming to pharmacropoeial specifications formed from the said novel crystaline form of quinapril hydrochloride of formula(I). The crystalline quinapril hydrochloride is in the form n...

A process for preparation of a novel crystalline form of quinapril hydrochloride of formula(I). A process for preparation of amorphous form of quinapril hydrochloride, of high purity and conforming to pharmacopoeial specifications, by the use of the novel crystalline quinapril hydrochloride as an intermediate. The s...

A controlled release formulation comprising less than about 40% of anti-epileptic drug, about 20% to about 50% of rate controlling polymer and silica having a particle size less than about 1 micron and specific surface area not less than 70m2/g, all weight percentages are based upon the total weight of the dosage fo...

A color stable controlled release pharmaceutical dosage from comprising HMG CoA reductase inhibitor, rate controlling polymers and one or more pharmaceutical excipients wherein the granules are independent of particle size.the pharmaceutical dosage form is free of alkalizing/buffering agents.A color stable controlle...

A novel crystalline form of atorvastatin sodium. The said crystalline atorvastatin sodium has characteristic X-ray powder diffraction pattern and is highly pure with purity above 99.5%.

The present invention is directed to substantially pure tiotropium bromide or its hydrate having reduced content of regioisomeric impurity (1R,2R,4S,5S,7s)-7-(2-hydroxy-2-(thiophen-2-yl)-2-(thiophen-3-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide of formula (2).

See Attachment

The present invention provides novel crystalline monohydrate form of Vortioxetine hydrobromide, process for its preparation and pharmaceutical composition thereof.

A process for the purification of 7-(4-bromobutoxy)-3,4- dihydrocarbostyril, substantially free of dimer impurity, said process comprising providing a solution of crude 7-(4-bromobutoxy)-3,4-dihydrocarbostyril containing the dimer impurity in an organic solvent selected from the group of halogenated hydrocarbon solv...

See Attachment

The present invention relates to a stereoselective glycosylation for the preparation of substituted 1,3-oxathiolane nucleoside in high yield and high optical purity. The invention specifically relates to a process of the preparation of Lamivudine using zirconium (IV) chloride (ZrCl4) as a catalyst in glycosylation. ...

The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating preventing and/or managing the diseases disorders syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating preventing managing ...

The present invention pertains to process for preparing nucleoside phosphoramidate and its intermediate. The present invention provides novel intermediate, its process for preparation and its use for the preparation of Sofosbuvir.

The present invention relates to a process for preparation of 17-monoesters of 17a, 21-dihydroxy steroids comprising hydrolysis of the corresponding 17a, 21-(1’-alkoxy)-1-substituted methylenedioxy steroids in the presence of an inorganic or organic acidic salt in a suitable solvent. Further, the present invention ...

The present invention relates to compound of formula II Formula II wherein R = -OCH(CH3)2, -CH3; or a pharmaceutically acceptable salt thereof. The present invention further relates to substantially pure cefixime proxetil; substantially pure cefixime axetil and their pharmaceutically acceptable salt thereof...

Disclosed are compounds of formula (I) for use as antiviral agents particularly as anti hepatitis virus C agents wherein R R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds either alone or in...

The present invention provides a novel process for the preparation of N-[(S)-(2,3,4,5,6-Pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-methylethyl ester (formula 2), by using phase transfer catalyst or surfactant.

The present invention relates to a process for the preparation of Levothyroxine and salts thereof. The process described in the present invention provides increase in the yields and purity comprising the use of sodium iodide and sodium hypochlorite as iodinating agent.

The present invention describes a novel, and industrially feasible process for preparation of Armodafinil. This process is easy, cost-effective and viable at all scales.

The present invention provides two processes for preparation of pure crystalline form B of flupirtine maleate comprising precipitation of flupirtine maleate from mixture of isopropanol and water.

An oral pharmaceutical composition for treatment psoriasis is provided which includes the ingredients of an extract from the leaves of the Argemone mexicana plant. Method for treating psoriasis using the composition is also disclosed.

Disclosed are compounds of formula (I) for use as antiviral agents particularly as anti hepatitis virus C agents wherein A B U R R m n and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds either alo...

The invention provides a process for manufacture of rifabutin comprising steps of: (a) Conversion of rifamycin-S to 3-amino-rifamycin-S in presence of sodium azide in an organic solvent such as formamide or methyl formamide at a temperature of about 33- 35°C, wherein the byproduct rifamycin-SV was simultaneously ...

The present invention provides novel process for preparation of azilsartan medoxomil (I). The present invention also provides novel intermediate compounds (V, R’ is ethyl), (VI, R’ is ethyl) and (VII, R’ is ethyl), useful for synthesis of azilsartan medoxomil (I).

The present invention provides crystalline hydrated form of sofosbuvir and a process for the preparation of crystalline hydrated form of sofosbuvir. The crystalline hydrated form of sofosbuvir disclosed herein may be useful in the formulation of pharmaceutical dosage forms.

The present invention relates to an improved and industrially feasible process for the preparation of compound of formula I. The present invention also involves preparation of the intermediate of compound B having enantiomeric excess of 99.6% and a novel compound of formula C.

The present invention provides process for preparation of cysteamine bitartrate comprising reacting cysteamine or its salt with tartaric acid. The present invention further provides crystalline form L1 of cysteamine bitartrate having characteristic diffraction peaks at 10.36, 14.54, 17.23, 18.03, 19.24, 20.76, 21.20...

The present invention relates to the purification of TNFR:Fc fusion protein. More specifically related to process of purification of TNFR:Fc fusion protein wherein the HCP is reduced. The present invention is directed to the use of mixed mode chromatography and/or affinity chromatography to produce TNFR:Fc fusion pr...

The present invention is directed to substantially pure teneligliptin hydrobromide of formula (1) or its hydrate having reduced content of teneligliptin sulfoxide impurity ((2S,4S)-4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-yl)(1-oxidothiazolidin-3-yl)methanone hemipentahydrobromide hydrate ...

The present invention relates to co-crystals of Metolazone with isonicotinamide, salicylic acid and 4-hydroxy benzoic acid, and process for their preparation.

The present invention relates to polyherbal eye drop composition(s) comprising mixture of herbs and excipients for treatment of eye disorders. More specifically, present invention relates to polyherbal eye drop composition(s) comprising mixture of herbs, vitamin(s) and excipients for treatment of eye disorders. Pres...